EUVIMEDEUVIMED entdecken
Crossref

Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid

Yusuke Inoue, Asuka Oda, Yusaku Maeda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, Mamiko Takahashi, Shiro Fujii, Shingen Nakamura, Hirokazu Miki, Masahiro Hiasa und 3 weitere

International Journal of Hematology · 2024

DOI: 10.1007/s12185-024-03763-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Hematology, 2024. Verfasst von Yusuke Inoue und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Technology, Tokushima University Hospital, Tokushima, Japan. Hauptthemen laut MEDLINE: Zoledronic Acid, Receptors, Antigen, T-Cell, gamma-delta, Lymphocyte Activation, Multiple Myeloma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Japanese Society of Hematology, University of Tokushima.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As multiple myeloma (MM) progresses, immune effector cells decrease in number and function and become exhausted. This remains an insurmountable clinical issue that must be addressed by development of novel modalities to revitalize anti-MM immunity. Human Vγ9Vδ2 T (Vδ2+ γδ T) cells serve as the first line of defense against pathogens as well as tumors and can be expanded ex vivo from peripheral blood mononuclear cells (PBMCs) upon treatment with amino-bisphosphonates in combination with IL-2. Here, we demonstrated that next-generation immunomodulators called cereblon E3 ligase modulators (CELMoDs), as well as lenalidomide and pomalidomide, expanded Th1-like Vδ2+ γδ T cells from PBMCs in the presence of zoledronic acid (ZA). However, the expansion of Th1-like Vδ2+ γδ T cells by these immunomodulatory drugs was abolished under IL-2 blockade, although IL-2 production was induced in PBMCs. BTN3A1 triggers phosphoantigen presentation to γδ T-cell receptors and is required for γδ T-cell expansion and activation. ZA but not these immunomodulatory drugs upregulated BTN3A1 in monocytes. These results suggest that immunomodulatory drugs and ZA have cooperative roles in expansion of Th1-like Vδ2+ γδ T cells, and provide the important knowledge for clinical application of human Vδ2+ γδ T cells as effector cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Zoledronic AcidReceptors, Antigen, T-Cell, gamma-deltaLymphocyte ActivationMultiple MyelomaDiphosphonatesImidazolesThalidomideHumansButyrophilinsInterleukin-2LenalidomideUbiquitin-Protein LigasesCell ProliferationAdaptor Proteins, Signal TransducingTh1 CellsLeukocytes, MononuclearAntigens, CD

Stichwörter der Autor:innen

CELMoDImmunotherapyMultiple myelomaVγ9Vδ2 T cellZoledronic acid

Substanzen

Zoledronic AcidReceptors, Antigen, T-Cell, gamma-deltaDiphosphonatesImidazolesThalidomideBTN3A1 protein, humanpomalidomideButyrophilinsInterleukin-2Lenalidomide

Autor:innen und Institutionen

  • Department of Medical Technology, Tokushima University Hospital, Tokushima, Japan.
  • Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, Tokushima, 770-8503, Japan.
  • Department of Hematology, Tokushima University Hospital, Tokushima, Japan.
  • Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, Tokushima, Japan.
  • Department of Orthodontics and Dentofacial Orthopedics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.

Förderung

  • Japan Society for the Promotion of Science
  • Japanese Society of Hematology
  • University of Tokushima
  • Bristol-Myers Squibb

Zitieren

APA

Inoue, Y., Oda, A., Maeda, Y., Sumitani, R., Oura, M., Sogabe, K., Maruhashi, T., Takahashi, M., Fujii, S., Nakamura, S., Miki, H., Hiasa, M., Teramachi, J., Harada, T., & Abe, M. (2024). Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03763-7

Vancouver

Inoue Y, Oda A, Maeda Y, Sumitani R, Oura M, Sogabe K, et al. Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid. International Journal of Hematology. 2024. doi:10.1007/s12185-024-03763-7

BibTeX
@article{Inoue2024,
  author = {Inoue, Yusuke and Oda, Asuka and Maeda, Yusaku and Sumitani, Ryohei and Oura, Masahiro and Sogabe, Kimiko and Maruhashi, Tomoko and Takahashi, Mamiko and Fujii, Shiro and Nakamura, Shingen and Miki, Hirokazu and Hiasa, Masahiro and Teramachi, Jumpei and Harada, Takeshi and Abe, Masahiro},
  title = {Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid},
  journal = {International Journal of Hematology},
  year = {2024},
  doi = {10.1007/s12185-024-03763-7}
}
Kostenlos starten →